Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | KARPAS-422; Karpas 422; KARPAS 422; Karpas422; KARPAS422; K422 |
| Species | Human |
| Cat.No | ABC-TC475S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
KARPAS-422 is a human B-cell non-Hodgkin’s lymphoma (NHL) cell line established from the pleural effusion of a chemotherapy-resistant lymphoma patient, typically an adult. It shows features of mature B-cell neoplasms and displays lymphoblast morphology with irregular cell shape. The cells grow in suspension in RPMI1640 medium supplemented with 10% fetal bovine serum, incubated at 37 °C with 5% CO₂. KARPAS-422 expresses high levels of CD19, CD37, surface immunoglobulins (predominantly IgM and IgG), and CDw52 (CAMPATH-1), shows weak expression of CD10, and lacks CD5 expression. Its unique antigen profile and resistance to chemotherapy make it a valuable model for studying the biology and treatment response of B-cell lymphomas.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
KARPAS-422 can be used to explore the mechanism of Cyclin D1-dependent cell cycle dysregulation and the role of abnormal BCR (B cell receptor) signaling pathway in lymphoma progression. In addition, this cell line is also widely used to evaluate the efficacy of BTK inhibitors (such as ibrutinib), BCL-2 inhibitors (such as venetoclax) and proteasome inhibitors, helping to develop new targeted therapies.
